MIDDLE EAST & NORTH AFRICA

We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2019 financial year.

Key Countries

Algeria
Egypt
Morocco
Saudi Arabia
United Arab Emirates

Contribution to Group revenue (%)

Revenue by segment (%)

MENA growth will be mainly driven by Eqypt, UAE and Algeria over the next 3 years. Saudi Arabia is expected to be the largest market but the slowest growing
The MENA reqion is expected to grow in USD by value at 5.4% p.a. 4 year CAGR between 2018 and 2022

Source: IQVIA Market Prognosis

STATISTICS

Number of products launched:

7

(2018: 5)^#

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

USD107 million

3 – 5 years

USD145 million

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover:

19,2%

(2018: 10,9%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

^# The number of product launches has been restated to take into account discontinued operations.

Revenue	2019 R'million	2018 (CER) R'million	change %
Total	1 056	1 032	2
Regional Brands	701	651	8
Sterile Focus Brands	355	381	(7)
Anaesthetics Brands	237	211	12
Thrombosis Brands	118	170	(31)

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.